P. Hirth

发表

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.

S. Hubbard, J. Schlessinger, M. Mohammadi, 1997, Science.

The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.

N. Gretz, G. Schley, P. Hirth, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Vemurafenib: the first drug approved for BRAF-mutant cancer

P. Hirth, K. Nolop, G. Bollag, 2012, Nature Reviews Drug Discovery.

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Kam Y. J. Zhang, K. Flaherty, J. Sosman, 2010, Nature.

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Kam Y. J. Zhang, James Tsai, Nikolas K. Haass, 2008, Proceedings of the National Academy of Sciences.

Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

Kam Y. J. Zhang, G. Habets, P. Hirth, 2013, Proceedings of the National Academy of Sciences.

Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.

G. Mcmahon, P. Hirth, A. Levitzki, 1998, The Journal of pharmacology and experimental therapeutics.

Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension

P. Hirth, N. Voelkel, R. Tuder, 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model.

J. Stewart, P. Hirth, N. Voelkel, 2002, Canadian journal of physiology and pharmacology.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.

P. Hirth, N. Voelkel, R. Tuder, 2000, The Journal of clinical investigation.

The metabolism of recombinant erythropoietin in the isolated perfused rat liver.

P. Hirth, O. Nielsen, M. Egfjord, 2008, Liver.

Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.

G. Mcmahon, L. Sun, C. Tang, 1998, Journal of medicinal chemistry.

Molecular biology of erythropoietin.

P. Hirth, P. Hirth, P Scigalla, 1988, Contributions to nephrology.

Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

J. Dering, W. Tap, P. Hirth, 2010, Neoplasia.

Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines.

G. Mcmahon, P. Hirth, A. Levitzki, 1996, Bioorganic & medicinal chemistry.

RAF inhibitors that evade paradoxical MAPK pathway activation

James Tsai, Ying Zhang, Paul S. Lin, 2015, Nature.

Cell-free synthesis of enterotoxin of E. coli from a cloned gene

R. Lathe, P. Hirth, J. Lecocq, 1980, Nature.

Evaluation of the stability of human erythropoietin in samples for radioimmunoassay

P. Hirth, A. Kurtz, C. Bauer, 1988, Klinische Wochenschrift.

Cell free synthesis of bacteriophage lambda replication proteins

H. Kluding, E. Fuchs, P. Hirth, 1977, FEBS letters.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.

G. Mcmahon, P. Hirth, A. Levitzki, 1998, The Journal of pharmacology and experimental therapeutics.